Table 6.

Time to progression and survival after the initial vaccination

	Initial stage	Peak IgM titer to polySA	TTP (mo)	Site of progression	Survival (mo)
10 μg dose level
Patient 1	Extensive	1,280	1	Lung, LN	3
Patient 2	Extensive	5,120	8	LN, adrenal, liver	29
Patient 3	Limited	80	4	Brain, lung, LN, bone	19
Patient 4	Limited	1,280	N/A	N/A	45+
Patient 5	Limited	2,560	N/A	N/A	72+
Patient 6	Limited	320	N/A	N/A	70+
Patient 7	Extensive	2,560	2	Unknown	6
Patient 8	Extensive	80	6	Lung	11
Patient 9	Limited	80	N/A	N/A	58
3 μg dose level
Patient 1	Extensive	0	5	Brain	11
Patient 2	Limited	160	3	Unknown	7
Patient 3	Limited	0	8	Lung, adrenal	37
Patient 4	Limited	40	N/A	N/A	56+
Patient 5	Limited	320	10	Liver	33
Patient 6	Extensive	320	2	Brain, liver	6
Patient 7	Extensive	0	4	Lung, LN	22
Patient 8	Limited	2,560	4	LN	13
Patient 9	Limited	2,560	3	Lung, liver	24

+ indicates the patient remains alive at the time of this analysis

N/A not applicable